Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

J&J made it into a nasal spray to get it into the brain quickly ... about the risk of sedation and dissociation, respiratory depression, suicidal thoughts and abuse or misuse of the drug, among ...

In a new study on mice, an experimental antibody treatment reduced the lingering after-effects of head injuries.

Spravato is a first-of-its-kind medication to help manage treatment-resistant depression, according to the pharmaceutical company. The nasal spray can be given to people who haven’t seen ...

TBI occurs when the brain is damaged by an external force, like a nasty tackle or a hard punch (or getting pulled over by ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

A study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...

A treatment tested by researchers in Boston found it improves motor function, coordination and spatial memory in mice. But it ...